Physicians at the University of Illinois Hospital & Health Sciences System have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings.
The transplants were the first to be performed outside of the National Institutes of Health campus in Maryland, where the procedure was developed. Physicians there have treated 30 patients, with an 87 percent success rate. The results of the phase I/II clinical trial at UI Health, in which 92 percent of treated patients were cured, are published online in the journal Biology of Blood & Marrow Transplantation.
The new technique eliminates the need for chemotherapy to prepare the patient to receive the transplanted cells and offers the prospect of cure for tens of thousands of adults suffering from sickle cell disease.
About 90 percent of the approximately 450 patients who have received stem cell transplants for sickle cell disease have been children. Chemotherapy has been considered too risky for adult patients, who are often more weakened than children by the disease.
“Adults with sickle cell disease are now living on average until about age 50 with blood transfusions and drugs to help with pain crises, but their quality of life can be very low,” says Dr. Damiano Rondelli, chief of hematology/oncology and director of the blood and marrow transplant program at UI Health, and corresponding author on the paper.
“Now, with this chemotherapy-free transplant, we are curing adults with sickle cell disease, and we see that their quality of life improves vastly within just one month of the transplant,” said Rondelli, who is also the Michael Reese Professor of Hematology in the UIC College of Medicine. “They are able to go back to school, go back to work, and can experience life without pain.”
Sickle cell disease is inherited. It primarily affects people of African descent, including about one in every 500 African Americans born in the U.S. The defect causes the oxygen-carrying red blood cells to be crescent shaped, like a sickle. The misshapen cells deliver less oxygen to the body’s tissues, causing severe pain and eventually stroke or organ damage.
Doctors have known for some time that bone marrow transplantation from a healthy donor can cure sickle cell disease. But few adults were transplanted because high-dose chemotherapy was needed to kill off the patients’ own blood-forming cells — and their entire immune system, to prevent rejection of the transplanted cells, leaving patients open to infection.
In the new procedure, patients receive immunosuppressive drugs just before the transplant, along with a very low dose of total body irradiation — a treatment much less harsh and with fewer potentially serious side effects than chemotherapy.
Next, donor cells from a healthy and tissue-matched sibling are transfused into the patient. Stem cells from the donor produce healthy new blood cells in the patient, eventually in sufficient quantity to eliminate symptoms. In many cases, sickle cells can no longer be detected. Patients must continue to take immunosuppressant drugs for at least a year.
In the reported trial, the researchers transplanted 13 patients, 17 to 40 years of age, with a stem cell preparation from the blood of a tissue-matched sibling. Healthy sibling donor-candidates and patients were tested for human leukocyte antigen, a set of markers found on cells in the body. Ten of these HLA markers must match between the donor and the recipient for the transplant to have the best chance of evading rejection.
In a further advance of the NIH procedure, physicians at UI Health successfully transplanted two patients with cells from siblings who matched for HLA but had a different blood type.
In all 13 patients, the transplanted cells successfully took up residence in the marrow and produced healthy red blood cells. One patient who failed to follow the post-transplant therapy regimen reverted to the original sickle cell condition.
None of the patients experienced graft-versus-host disease, a condition where immune cells originating from the donor attack the recipient’s body.
One year after transplantation, the 12 successfully transplanted patients had normal hemoglobin concentrations in their blood and better cardiopulmonary function. They reported less pain and improved health and vitality.
Four of the patients were able to stop post-transplantation immunotherapy without transplant rejection or other complications.
The Latest on: Sickle cell disease
via Google News
The Latest on: Sickle cell disease
- NHRC to introduce drugs for Sickle Cell in childrenon February 3, 2020 at 8:25 am
Navrongo (U/E) Feb. 3, GNA - Dr Patrick Ansah, the Head of Clinical Science Department at the Navrongo Health Research Centre (NHRC) in the Kassena-Nankana Municipality of the Upper East Region says ...
- 'I have sickle cell, but sickle cell doesn’t have me’: While raising awareness, Chicago man, 25, dies from illnesson January 31, 2020 at 4:29 pm
On Jan. 14, early in the morning, Powell died due to complications from his sickle cell disease. He turned 25 two days before his death. The ongoing snow didn’t stop family, friends, fraternity ...
- S.C. student battling sickle cell disease gets surprise Super Bowl trip of a lifetimeon January 30, 2020 at 3:30 pm
Braden Green suffers from sickle cell disease, and recently received life-saving blood transfusions when he was diagnosed with acute chest syndrome. He and his family work to advocate for blood ...
- Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell Disease–Related Painon January 30, 2020 at 6:16 am
Patients had never been particularly enthusiastic about using opioids to treat their pain related to sickle cell disease, but they are more cautious now, especially as they are often meet with ...
- Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Diseaseon January 29, 2020 at 5:04 am
Managing people with sickle cell disease and complex chronic pain is difficult and requires some trial and error, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for ...
- Decoding sickle cell diseaseon January 28, 2020 at 6:51 am
Every year, approximately 300,000 babies are born with sickle cell disease. When Stephanie learned that Lamarcus had tested positive for sickle cell, she couldn't stop crying. "Then I thought ...
- Pfizer cans early-stage trials for cancer, sickle cell targetson January 28, 2020 at 5:36 am
The drug is aimed at sickle cell disease, caused by an inherited alteration in a gene that instructs the making of the beta-globin subunit of hemoglobin, the protein responsible for carrying oxygen in ...
- 'We’re having to scramble:' Blood bank staff say more donors needed to treat sickle cell diseaseon January 27, 2020 at 9:23 am
For many sickle cell patients in eastern Iowa, UIHC is the closest medical facility that can provide the necessary blood transfusions.
- Sickle Cell: NBA to sponsor mandatory Genotype Bill in Ekition January 27, 2020 at 8:35 am
Worried at the alarming rate young people die in the country as a result of sickle cell disease, Nigerian Bar Association(NBA), Ado -Ekiti branch has said it would sponsor a private bill that would ...
- Novartis, GBT sickle cell drugs too expensive, draft U.S. report sayson January 24, 2020 at 8:41 am
Sickle cell disease drugs made by Novartis and Global Blood Therapeutics (GBT) may not be cost effective at current prices, a draft report published on Friday suggested, widening the debate over U.S.
via Bing News